CT
GILD icon

Cambridge Trust’s Gilead Sciences GILD Stock Holding History

Cambridge Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$68.1K Buy
930
+55
+6% +$4.23K ﹤0.01% 392
2023
Q4 		$70.9K Hold
875
– – ﹤0.01% 381
2023
Q3 		$65.6K Sell
875
-60
-6% -$4.62K ﹤0.01% 389
2023
Q2 		$72.1K Sell
935
-206
-18% -$16.4K ﹤0.01% 389
2023
Q1 		$94.7K Sell
1,141
-173
-13% -$14.3K ﹤0.01% 361
2022
Q4 		$113K Sell
1,314
-60
-4% -$4.75K 0.01% 345
2022
Q3 		$85K Sell
1,374
-113
-8% -$7.13K ﹤0.01% 387
2022
Q2 		$92K Sell
1,487
-87
-6% -$5.39K ﹤0.01% 404
2022
Q1 		$94K Sell
1,574
-403
-20% -$25.8K ﹤0.01% 433
2021
Q4 		$144K Buy
+1,977
New +$136K ﹤0.01% 382
2016
Q3 		– Sell
-2,711
Closed -$226K – 259
2016
Q2 		$226K Buy
2,711
+260
+11% +$23.1K 0.02% 231
2016
Q1 		$225K Sell
2,451
-13
-0.5% -$1.17K 0.02% 210
2015
Q4 		$249K Buy
+2,464
New +$256K 0.02% 192

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cambridge Trust's GILD Position: Q1 2024 in Review

Cambridge Trust increased its Gilead Sciences (GILD) stake by 6.3% in Q1 2024, buying an estimated $4.23K and bringing the position to 930 shares worth $68.1K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Cambridge Trust first reported a position in GILD in Q4 2015 and has held it in 13 quarters since. The position peaked at $249K in Q4 2015. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Cambridge Trust held 930 shares of Gilead Sciences worth $68.1K as of Q1 2024.
  • Cambridge Trust bought 55 Gilead Sciences shares in Q1 2024, an estimated $4.23K.
  • Gilead Sciences made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #392 holding.
  • Cambridge Trust first reported a position in Gilead Sciences in Q4 2015 and has held it in 13 quarters since.
  • Cambridge Trust's Gilead Sciences position peaked at $249K in Q4 2015.
  • 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.